Expanded access to highly active antiretroviral therapy: A potentially powerful strategy to curb the growth of the HIV epidemic

Journal of Infectious Diseases

Volumn 198, Issue 1, 2008, Pages 59-67

  Lima, Viviane D ^a,c   Johnston, Karissa ^b,c   Hogg, Robert S ^a,d   Levy, Adrian R ^b,c   Harrigan, P Richard ^a,c   Anema, Aranka ^a   Montaner, Julio S G ^a,c  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b ST PAUL S HOSPITAL   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d SIMON FRASER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EMTRICITABINE PLUS LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CANADA; EPIDEMIC; HEALTH CARE COST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATHEMATICAL MODEL; PRIORITY JOURNAL; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRITISH COLUMBIA; CD4 LYMPHOCYTE COUNT; DELIVERY OF HEALTH CARE; DISEASE OUTBREAKS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MODELS, BIOLOGICAL; POVERTY; PROBABILITY; RNA, VIRAL; SOCIOECONOMIC FACTORS;

EID: 46349100736     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/588673     Document Type: Article

References (50)

1. Piot P. Why AIDS is exceptional. AIDS Matters, 2005. Available at: http://www.aidsmatters.org/archives/100-Why-AIDS-is-Exceptional.html. Accessed 10 March 2007.
2. Joint United Nations Programme on HIV/AIDS. 2006 report on the global AIDS epidemic. 2006. Available at: http://www.unaids.org/en/HIV_data/ 2006GlobalReport/default.asp. Accessed 10 March 2007.
3. Gayle HD. Expanding access to HIV prevention. AIDS Res Ther 2006; 3:2.
4. Joint United Nations Programme on HIV/AIDS. Financing the expanded response to AIDS: HIV vaccine and microbicide research and development. 2005. Available at: http://www.hivresourcetracking.org/. Accessed 10 March 2007.
5. Chen LF, Hoy J, Lewin SR. Ten years of highly active antiretroviral therapy for HIV infection. Med J Aust 2007; 186:146-51.
6. Montaner JS, Hogg R, Wood E, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 2006; 368:531-6.
7. Joint United Nations Programme on HIV/AIDS. Resource needs for an expanded response to AIDS in low- and middle-income countries. 2006. Available at: http://data.unaids.org/publications/IRC-pub06/ resourceneedsreport_24jun05_en.pdf. Accessed 10 March 2007.
8. Kerr T, Kaplan K, Suwannawong P, Jurgens R, Wood E. The Global Fund to Fight AIDS, Tuberculosis and Malaria: funding for unpopular public-health programmes. Lancet 2004; 364:11-12.
9. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. Top HIV Med 2006; 14:827-43.
10. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2006. Available at: http://AIDSinfo.nih.gov. Accessed 29 May 2007.
11. World Health Organization. Progress on global access to HIV antiretroviral therapy: an update on 3 by 5. 2006. Available at: http://www.who.int/hiv/3by5evaluation/en/. Accessed 5 December 2006.
12. World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. 2006. Available at: http://www.who.int/ hiv/pub/guidelines/en/. Accessed 5 December 2006.
13. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: towards universal access. 2006. Available at: http://www.who.int/hiv/pub/guidelines/en/. Accessed 5 December 2006.
14. Hogg RS, Rhone SA, Yip B, et al. Antiviral effect of double and triple drug combinations amongst HIV- infected adults: lessons from the implementation of viral load-driven antiretroviral therapy. AIDS 1998; 12:279-84.
15. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352:1725-30.
16. Cu-Uvin S, Caliendo AM, Reinert S, et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS 2000; 14:415-21.
17. Vernazza PL, Gilliam BL, Flepp M, et al. Effect of antiviral treatment on the shedding of HIV-1 in semen. AIDS 1997; 11:1249-54.
18. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354:795-802.
19. De Cock KM, Fowler MG, Mercier E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA 2000; 283:1175-82.
20. Karon JM, Fleming PL, Steketee RW, De Cock KM. HIV in the United States at the turn of the century: an epidemic in transition. Am J Public Health 2001; 91:1060-8.
21. Tovanabutra S, Robison V, Wongtrakul J, et al. Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. J Acquir Immune Defic Syndr 2002; 29:275-83.
22. Musicco M, Lazzarin A, Nicolosi A, et al. Italian study group on HIV heterosexual transmission. Arch Intern Med 1994; 154:1971-6.
23. Castilla J, Del Romero J, Hernando V, et al. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr 2005; 40:96-101.
24. Hosseinipour M, Cohen MS, Vernazza PL, Kashuba AD. Can antiretroviral therapy be used to prevent sexual transmission of human immunodeficiency virus type 1? Clin Infect Dis 2002; 34:1391-5.
25. Blower SM, Gershengorn HB, Grant RM. A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science 2000; 287:650-4.
26. Law MG, Prestage G, Grulich A, Van de Ven P, Kippax S. Modelling the effect of combination antiretroviral treatments on HIV incidence. AIDS 2001; 15:1287-94.
27. Velasco-Hernandez JX, Gershengorn HB, Blower SM. Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? Lancet Infect Dis 2002; 2:487-93.
28. Abbas UL, Anderson RM, Mellors JW. Potential impact of antiretroviral therapy on HIV-1 transmission and AIDS mortality in resource-limited settings. J Acquir Immune Defic Syndr 2006; 41:632-41.
29. Bunnell R, Ekwaru JP, Solberg P, et al. Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS 2006; 20:85-92.
30. Fang CT, Hsu HM, Twu SJ, et al. Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis 2004; 190:879-85.
31. Richman DD. Human immunodeficiency virus. London: International Medical Press, 2006.
32. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921-9.
33. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-54.
34. Lima VD, Hogg RS, Harrigan PR, et al. Continued improvement in survival among HIV infected individuals following initiation of triple and boosted combination antiretroviral regimens. AIDS 2007; 21:685-92.
35. British Columbia Centre of Disease Control. HIV statistics 2005. 2005. Available at: http://www.bccdc.org/content.php?item 5. Accessed 15 January 2007.
36. British Columbia Centre of Disease Control. HIV statistics 2004. 2004. Available at: http://www.bccdc.org/content.php?item 5. Accessed 15 January 2007.
37. Drummond MF, Stoddart GL, Torrance GW. Methods for economic evaluation of health care programmes. Oxford: Oxford Medical Publications, 1998.
38. Wood SN. Generalized additive models: an introduction with R. New York: Chapman & Hall/CRC, 2006.
39. Hogg RS, Bangsberg DR, Lima VD, et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med 2006; 3:e356.
40. D'Aquila RT, Schapiro JM, Brun-Vezinet F, et al. Drug resistance mutations in HIV-1. Top HIV Med 2002; 10:21-5.
41. Lima VD, Johnson K, Hogg RS, et al. Modeling the impact of increasing utilization of HAART on HIV incidence in settings with multiple sources of infection [poster 978]. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections (Los Angeles). Alexandria, VA: Foundation for Retrovirology and Human Health, 2007.
42. Salomon JA, Hogan DR, Stover J, et al. Integrating HIV prevention and treatment: from slogans to impact. PLoS Med 2005; 2:e16.
43. Boily MC, Bastos FI, Desai K, Masse B. Changes in the transmission dynamics of the HIV epidemic after the wide-scale use of antiretroviral therapy could explain increases in sexually transmitted infections: results from mathematical models. Sex Transm Dis 2004; 31:100-13.
44. Gray RH, Li X, Wawer MJ, et al. Stochastic simulation of the impact of antiretroviral therapy and HIV vaccines on HIV transmission, Rakai, Uganda. Rakai Project Group. AIDS 2003; 17:1941-51.
45. Blower SM, Aschenbach AN, Gershengorn HB, Kahn JO. Predicting the unpredictable: transmission of drug-resistant HIV. Nat Med 2001; 7:1016-20.
46. British Columbia Centre of Disease Control. 2005 STD annual report. 2005. Available at: http://www.bccdc.org/content.php?item 5. Accessed 15 January 2007.
47. Baggaley RF, Garnett GP, Ferguson NM. Modelling the impact of antiretroviral use in resource-poor settings. PLoS Med 2006; 3:e124.
48. Baggaley RF, Ferguson NM, Garnett GP. The epidemiological impact of antiretroviral use predicted by mathematical models: a review. Emerg Themes Epidemiol 2005; 2:9.
49. Cormick AW, Walensky RP, Lipsitch M, et al. The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men. Clin Infect Dis 2007; 44:1115-22.
50. Griffiths JD, Lawson ZF, Williams JE. Modelling treatment effects in the HIV/AIDS epidemic. J Oper Res Soc 2006; 57:1413-24.